Cilostazol
- cilostazol
- 73963-72-1
- Pletal
- Cilostazole
- Pletaal
- Create:2005-03-25
- Modify:2025-01-18
- 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
- cilostazol
- OPC 13013
- OPC-13013
- Pletal
- cilostazol
- 73963-72-1
- Pletal
- Cilostazole
- Pletaal
- OPC-13013
- Cilostazolum
- OPC-21
- Cilostazolum [INN-Latin]
- OPC 21
- OPC 13013
- 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one
- CHEBI:31401
- 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
- 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
- 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
- NSC-758936
- BRN 3632107
- DTXSID9045132
- UNII-N7Z035406B
- 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
- MFCD00866780
- N7Z035406B
- 6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one
- MLS000028470
- DTXCID7025132
- HSDB 8312
- 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
- 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
- NSC 758936
- Cilostazol [USAN:USP:INN:BAN:JAN]
- NCGC00015207-07
- SMR000058428
- Cilostazolum (INN-Latin)
- 2(1H)-Quinolinone, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-
- 2(1H)-quinolinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-
- 2(1H)-Quionlinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-
- 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone
- CILOSTAZOL (MART.)
- CILOSTAZOL [MART.]
- CILOSTAZOL (USP-RS)
- CILOSTAZOL [USP-RS]
- CILOSTAZOL (USP MONOGRAPH)
- CILOSTAZOL [USP MONOGRAPH]
- 6-[4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
- Cilostazol (USAN:USP:INN:BAN:JAN)
- CAS-73963-72-1
- Pletal (TN)
- SR-01000003107
- 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy)-3,4-dihydro-1H-quinolin-2-one
- 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
- Cilostazol,(S)
- Cilostazolum (Latin)
- Cilostazol (Standard)
- Tocris-1692
- CILOSTAZOL [MI]
- Opera_ID_488
- CILOSTAZOL [INN]
- CILOSTAZOL [JAN]
- Spectrum2_001118
- Spectrum3_001170
- Spectrum4_000772
- Spectrum5_001762
- CILOSTAZOL [USAN]
- Lopac-C-0737
- CILOSTAZOL [VANDF]
- CHEMBL799
- C 0737
- CILOSTAZOL [WHO-DD]
- Lopac0_000218
- REGID_for_CID_2754
- SCHEMBL16128
- BSPBio_002759
- KBioGR_001184
- MLS000758281
- MLS000759507
- MLS001076067
- MLS002153891
- SPECTRUM1505230
- SPBio_001256
- Cilostazol (JP18/USP/INN)
- GTPL7148
- CILOSTAZOL [ORANGE BOOK]
- KBio3_002259
- BCPP000279
- HMS1922N15
- HMS2093M14
- HMS2096F16
- HMS2234C06
- HMS3260L17
- HMS3268O09
- HMS3412B18
- HMS3654J13
- HMS3676B18
- HMS3713F16
- Pharmakon1600-01505230
- BCP03724
- Tox21_110098
- Tox21_500218
- BDBM50225508
- CCG-39646
- HY-17464R
- NSC758936
- s1294
- AKOS015855512
- Cilostazol, >=98% (HPLC), powder
- OPC 13013; OPC 21; Pletaal
- Tox21_110098_1
- AC-4334
- BCP9000530
- CS-1759
- DB01166
- KS-5154
- LP00218
- SDCCGSBI-0050206.P003
- NCGC00015207-01
- NCGC00015207-02
- NCGC00015207-03
- NCGC00015207-04
- NCGC00015207-05
- NCGC00015207-06
- NCGC00015207-08
- NCGC00015207-09
- NCGC00015207-10
- NCGC00015207-11
- NCGC00015207-12
- NCGC00015207-25
- NCGC00022153-02
- NCGC00022153-04
- NCGC00022153-05
- NCGC00022153-06
- NCGC00022153-07
- NCGC00260903-01
- HY-17464
- BCP0726000145
- RETAL;PLETAL;OPC 21;PLETAAL;Cilostal
- SBI-0050206.P002
- C2587
- EU-0100218
- NS00009762
- SW199053-2
- D01896
- F20538
- AB00382988-14
- AB00382988_15
- AB00382988_16
- Q258591
- Q-200854
- SR-01000003107-2
- SR-01000003107-4
- SR-01000003107-7
- BRD-K67017579-001-04-2
- BRD-K67017579-001-05-9
- BRD-K67017579-001-07-5
- BRD-K67017579-001-13-3
- BRD-K67017579-001-17-4
- BRD-K67017579-001-26-5
- BRD-K67017579-001-27-3
- BRD-K67017579-001-28-1
- SR-01000003107-10
- Cilastatin sodium, Antibiotic for Culture Media Use Only
- Z1501485368
- Cilostazol, United States Pharmacopeia (USP) Reference Standard
- 6-[4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
- 6-[4-(l-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxyl]-3,4-dihydrocarbostyril
- Cilostazol, Pharmaceutical Secondary Standard; Certified Reference Material
- 6-(4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY)QUINOLINE-2,3(1H,4H)-DIONE
- 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butyloxy)-3,4-dihydroquinolin-2(1H)-one
- 6-[4-(1-Cyclohexyl-5-tetrazolyl)butoxy]-1,2,3,4- tetrahydro-2-oxoquinolinone
199.48 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
194.26 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
181.67 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
195.62 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
193.043243 2788
125.016205 2384
97.024185 1460
151.032104 1288
183.05838 1112
370.225769 100
288.147003 72.72
125.083145 19.07
371.226746 18.30
289.148621 9.59
370.225769 100
288.147003 72.72
125.083145 19.07
371.226746 18.30
289.148621 9.59
Use (kg; approx.) in Germany (2009): >1000
Consumption (g per capita; approx.) in Germany (2009): 0.0122
Calculated removal (%): 49
P203, P280, P318, P405, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)
Aggregated GHS information provided per 3 reports by companies from 2 notifications to the ECHA C&L Inventory.
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
In publications of the multiple, large prospective trials of cilostazol therapy, rates of serum ALT elevations during therapy were not provided. Furthermore, there were no reported instances of clinically apparent acute liver injury. Since its approval and wide scale use, there have been no published reports of hepatotoxicity attributed to cilostazol. Nevertheless, the current product label mentions that instances of serum enzyme elevations and hepatitis have been reported to the sponsor. The time of onset, clinical pattern and course of liver test abnormalities during cilostazol therapy have not been reported.
Likelihood score: E (unlikely cause of clinically apparent liver injury).
M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007
M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015
◉ Summary of Use during Lactation
Because no information is available on the use of cilostazol during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. If it is used by a nursing mother, monitor the infant for bruising and bleeding.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Patents are available for this chemical structure:
https://patentscope.wipo.int/search/en/result.jsf?inchikey=RRGUKTPIGVIEKM-UHFFFAOYSA-N
- Avoid grapefruit products.
- Take on an empty stomach. A high fat meal will increase absorption.
- CAS Common ChemistryLICENSEThe data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc/4.0/
- ChemIDplusCilostazol [USAN:USP:INN:BAN:JAN]https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0073963721ChemIDplus Chemical Information Classificationhttps://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
- DrugBankLICENSECreative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)https://www.drugbank.ca/legal/terms_of_useCilostazolhttps://www.drugbank.ca/drugs/DB01166
- DTP/NCILICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuse
- EPA DSSToxCompTox Chemicals Dashboard Chemical Listshttps://comptox.epa.gov/dashboard/chemical-lists/
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-notice6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-onehttps://echa.europa.eu/substance-information/-/substanceinfo/100.215.8976-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one (EC: 689-122-9)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/221151
- FDA Global Substance Registration System (GSRS)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Hazardous Substances Data Bank (HSDB)
- Human Metabolome Database (HMDB)LICENSEHMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.http://www.hmdb.ca/citingHMDB0015297_msms_374752https://hmdb.ca/metabolites/HMDB0015297#spectra
- CCSbaseCCSbase Classificationhttps://ccsbase.net/
- ChEBI
- FDA Pharm ClassesLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingFDA Pharmacological Classificationhttps://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
- LiverTox
- NCI Thesaurus (NCIt)LICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuseNCI Thesaurushttps://ncit.nci.nih.gov
- Open TargetsLICENSEDatasets generated by the Open Targets Platform are freely available for download.https://platform-docs.opentargets.org/licence
- ChEMBLLICENSEAccess to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).http://www.ebi.ac.uk/Information/termsofuse.htmlChEMBL Protein Target Treehttps://www.ebi.ac.uk/chembl/g/#browse/targets
- Comparative Toxicogenomics Database (CTD)LICENSEIt is to be used only for research and educational purposes. Any reproduction or use for commercial purpose is prohibited without the prior express written permission of NC State University.http://ctdbase.org/about/legal.jsp
- Drug Gene Interaction database (DGIdb)LICENSEThe data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.http://www.dgidb.org/downloadsCILOSTAZOLhttps://www.dgidb.org/drugs/rxcui:21107
- IUPHAR/BPS Guide to PHARMACOLOGYLICENSEThe Guide to PHARMACOLOGY database is licensed under the Open Data Commons Open Database License (ODbL) https://opendatacommons.org/licenses/odbl/. Its contents are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-sa/4.0/)https://www.guidetopharmacology.org/about.jsp#licenseGuide to Pharmacology Target Classificationhttps://www.guidetopharmacology.org/targets.jsp
- Therapeutic Target Database (TTD)
- ClinicalTrials.govLICENSEThe ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
- Crystallography Open Database (COD)LICENSEAll data in the COD and the database itself are dedicated to the public domain and licensed under the CC0 License. Users of the data should acknowledge the original authors of the structural data.https://creativecommons.org/publicdomain/zero/1.0/
- The Cambridge Structural Database
- DailyMed
- Drug Induced Liver Injury Rank (DILIrank) DatasetLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- NORMAN Suspect List ExchangeLICENSEData: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0https://creativecommons.org/licenses/by/4.0/CILOSTAZOLNORMAN Suspect List Exchange Classificationhttps://www.norman-network.com/nds/SLE/
- Drugs and Lactation Database (LactMed)
- Drugs@FDALICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- EU Clinical Trials Register
- FDA Orange BookLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- National Drug Code (NDC) DirectoryLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Japan Chemical Substance Dictionary (Nikkaji)
- KEGGLICENSEAcademic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial licensehttps://www.kegg.jp/kegg/legal.htmlTherapeutic category of drugs in Japanhttp://www.genome.jp/kegg-bin/get_htext?br08301.kegUSP drug classificationhttp://www.genome.jp/kegg-bin/get_htext?br08302.kegAnatomical Therapeutic Chemical (ATC) classificationhttp://www.genome.jp/kegg-bin/get_htext?br08303.kegTarget-based classification of drugshttp://www.genome.jp/kegg-bin/get_htext?br08310.kegDrugs listed in the Japanese Pharmacopoeiahttp://www.genome.jp/kegg-bin/get_htext?br08311.keg
- MassBank of North America (MoNA)LICENSEThe content of the MoNA database is licensed under CC BY 4.0.https://mona.fiehnlab.ucdavis.edu/documentation/license
- Metabolomics Workbench
- NIPH Clinical Trials Search of Japan
- NLM RxNorm TerminologyLICENSEThe RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
- PharmGKBLICENSEPharmGKB data are subject to the Creative Commons Attribution-ShareALike 4.0 license (https://creativecommons.org/licenses/by-sa/4.0/).https://www.pharmgkb.org/page/policies
- PharosLICENSEData accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution.https://pharos.nih.gov/about
- SpectraBase
- Springer Nature
- Thieme ChemistryLICENSEThe Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc-nd/4.0/
- WHO Anatomical Therapeutic Chemical (ATC) ClassificationLICENSEUse of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.https://www.whocc.no/copyright_disclaimer/
- Wikidatacilostazolhttps://www.wikidata.org/wiki/Q258591
- WikipediaOrnidazolehttps://en.wikipedia.org/wiki/OrnidazoleCilostazolhttps://en.wikipedia.org/wiki/Cilostazol
- Wiley
- Medical Subject Headings (MeSH)LICENSEWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.https://www.nlm.nih.gov/copyright.htmlFibrinolytic Agentshttps://www.ncbi.nlm.nih.gov/mesh/68005343Neuroprotective Agentshttps://www.ncbi.nlm.nih.gov/mesh/68018696Vasodilator Agentshttps://www.ncbi.nlm.nih.gov/mesh/68014665Platelet Aggregation Inhibitorshttps://www.ncbi.nlm.nih.gov/mesh/68010975Phosphodiesterase 3 Inhibitorshttps://www.ncbi.nlm.nih.gov/mesh/68058987Bronchodilator Agentshttps://www.ncbi.nlm.nih.gov/mesh/68001993
- PubChem
- GHS Classification (UNECE)GHS Classification Treehttp://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
- MolGenieMolGenie Organic Chemistry Ontologyhttps://github.com/MolGenie/ontology/
- PATENTSCOPE (WIPO)SID 388421207https://pubchem.ncbi.nlm.nih.gov/substance/388421207
- NCBI